Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be ...

It's common for clinical-stage biotech companies to post net losses, but the market wasn't forgiving of this one's latest.

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Recursion reported second-quarter revenue of $19.22 million, beating analyst estimates of $16.23 million, according to ...

Clinical-stage biotech Recursion Pharmaceuticals ' (NASDAQ: RXRX) stock took it on the chin in the first trading day of the ...

Guidance remains unchanged, with management projecting "over $100 million in partnership inflows by the end of 2026" and targeting a cash burn below $390 million in 2026. The company anticipates a ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.

Recursion Pharmaceuticals grew its share prices for a fourth straight day on Monday, adding 9.59 percent to close at $6.40 apiece as investors repositioned portfolios ahead of its second quarter ...